Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A bioassay using intestinal organoids to measure CFTR modulators in human plasma.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Mar 2015

Dekkers R, Vijftigschild L A W, Vonk A M, Kruisselbrink E, de Winter-de Groot K M, Janssens H M, van der Ent C K, Beekman J M

Abstract excerpt

Treatment efficacies of drugs depend on patient-specific pharmacokinetic and pharmacodynamic properties. Here, we developed an assay to measure functional levels of the CFTR potentiator VX-770 in human plasma and observed that VX-770 in plasma from different donors induced variable CFTR function in intestinal organoids. This assay can help to understand variability in treatment response to CFTR potentiators by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Antimutagenic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Assay

Share to Drug Monitoring

Share to Intestinal Mucosa

Share to Intestines

Share to Organoids

Share to Quinolones

Source

Identifiers

PMID: 25467948
DOI: 10.1016/j.jcf.2014.10.007

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A bioassay using intestinal organoids to measure CFTR modulators in human plasma.PMID 25467948Read ↗

Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.Semantic proximity Read ↗

Potentiator synergy in rectal organoids carrying S1251N, G551D, or F508del CFTR mutations.Semantic proximity Read ↗

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis.Semantic proximity Read ↗

Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration.Semantic proximity Read ↗

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.Semantic proximity Read ↗

High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposingSemantic proximity Read ↗

Intestinal organoids for Cystic Fibrosis researchSemantic proximity Read ↗

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.Semantic proximity Read ↗

FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis GenotypesSemantic proximity Read ↗

Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.Semantic proximity Read ↗

High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.